Početna › Melanom › Massachusetts
Kliničke studije za Melanom u državi Massachusetts
29 studija za Melanom traži sudionike na lokacijama u državi Massachusetts.
Gradovi u državi Massachusetts
Službeni tekst studije (engleski)
Phase 1/2 Study of Intravenous Injection of STX-003 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 2. lis 2026. · NCT07751042BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Baystate Medical Center, Springfield
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 25. ruj 2026. · NCT05136196Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
- Tufts Medical Center, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 24. ruj 2026. · NCT06047379A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
- Local Institution - 0124, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 16. ruj 2026. · NCT07492680DOC1021 Dendritic Cell Immunotherapy for Refractory Melanoma
- Massachusetts General Hospital Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT07288112Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 9. ruj 2026. · NCT04899908A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- Dana Farber Cancer Institute, Boston
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 2. ruj 2026. · NCT07070232Cryoablation+Ipilimumab+Nivolumab in Melanoma
- Massachusetts General Hospital Cancer Center, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 27. kol 2026. · NCT05779423Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
12 Months – 30 Years · Oba spola · Ažurirano 25. kol 2026. · NCT04851119Project: Every Child for Younger Patients With Cancer
- Massachusetts General Hospital Cancer Center, Boston
- Dana-Farber Cancer Institute, Boston
- Baystate Medical Center, Springfield
- i još 1
U tijeku regrutacijaOpažajna studija
Do 25 godina · Oba spola · Ažurirano 25. kol 2026. · NCT02402244Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 14. kol 2026. · NCT06425926A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants With Advanced Solid Tumors
- Massachusetts General Hospital Cancer Center, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 11. kol 2026. · NCT05592626A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 28. srp 2026. · NCT06150664A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
- Call for Information (Investigational Site 0026), Boston
U tijeku regrutacijaFaza 1/2
6 Months – 17 Years · Oba spola · Ažurirano 6. srp 2026. · NCT02332668Integrated Cancer Repository for Cancer Research
- Holyoke Medical Center, Holyoke
U tijeku regrutacijaOpažajna studijaZdravi dobrovoljci dobrodošli
Od 19 do 110 godina · Oba spola · Ažurirano 29. lip 2026. · NCT02012699Video Education With Result Dependent dIsclosure
- Dana Farber Cancer Institute, Boston
U tijeku regrutacija
Od 18 godina i više · Oba spola · Ažurirano 22. svi 2026. · NCT05225428Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 15. svi 2026. · NCT05379985ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 13. svi 2026. · NCT03686124Neoadjuvant Darovasertib in Primary Uveal Melanoma
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 6. svi 2026. · NCT07015190A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
- Dana Farber, Boston
U tijeku regrutacijaFaza 2/3
Od 18 godina i više · Oba spola · Ažurirano 22. tra 2026. · NCT06624644A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 2/3
Sve dobne skupine · Oba spola · Ažurirano 2. tra 2026. · NCT06581406Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center (BIDMC), Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 25. velj 2026. · NCT05549297ACTengine® IMA203 Combined With mRNA-4203
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. sij 2026. · NCT06946225Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 do 100 godina · Oba spola · Ažurirano 5. sij 2026. · NCT05428007SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Worcester
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 28. lis 2025. · NCT03452774A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 8. lis 2025. · NCT04370587A Study of GV20-0251 Monotherapy and GV20-0251 in Combination With Pembrolizumab in Participants With Solid Tumor Malignancies
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 13. velj 2025. · NCT05669430Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
- Massachusetts General Hospital, Boston
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 15. stu 2024. · NCT04787042Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
- Dana Farber Cancer Institute, Boston
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 18. ožu 2024. · NCT05280314Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.